Literature DB >> 26155431

Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy.

Anna R Kwilas1, Sofia R Gameiro1, Peter S Kim1, Anthony S Malamas1, James W Hodge1.   

Abstract

Androgen-deprivation therapy (ADT) induces prostate cancer immunogenic modulation (IM) by reducing human tumor cell expression of anti-apoptotic genes thus facilitating increased sensitivity to immune-mediated lysis. Through its stimulation of IM, ADT has been shown to synergize with active immunotherapy thereby significantly improving overall survival in a mouse model of prostate cancer.

Entities:  

Keywords:  Androgen-deprivation therapy; cancer immunotherapy; enzalutamide; immunogenic modulation; therapeutic cancer vaccine

Year:  2015        PMID： 26155431      PMCID： PMC4485836          DOI： 10.1080/2162402X.2015.1009303

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors:  James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 2.  EAU guidelines on prostate cancer.

Authors:  Axel Heidenreich; Gunnar Aus; Michel Bolla; Steven Joniau; Vsevolod B Matveev; Hans Peter Schmid; Filliberto Zattoni
Journal:  Eur Urol       Date:  2007-09-19       Impact factor: 20.096

Review 3.  Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically.

Authors:  Charles J Ryan; Donald J Tindall
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

4.  Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.

Authors:  Andressa Ardiani; Benedetto Farsaci; Connie J Rogers; Andy Protter; Zhimin Guo; Thomas H King; David Apelian; James W Hodge
Journal:  Clin Cancer Res       Date:  2013-09-18       Impact factor: 12.531

5.  Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.

Authors:  James L Gulley; Philip M Arlen; Ravi A Madan; Kwong-Yok Tsang; Mary P Pazdur; Lisa Skarupa; Jacquin L Jones; Diane J Poole; Jack P Higgins; James W Hodge; Vittore Cereda; Matteo Vergati; Seth M Steinberg; Susan Halabi; Elizabeth Jones; Clara Chen; Howard Parnes; John J Wright; William L Dahut; Jeffrey Schlom
Journal:  Cancer Immunol Immunother       Date:  2009-11-05       Impact factor: 6.968

6.  Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer.

Authors:  Helen H L Chiu; Theresa M K Yong; Jun Wang; Yuwei Wang; Robert L Vessella; Takeshi Ueda; Yu-Zhuo Wang; Marianne D Sadar
Journal:  Cancer Lett       Date:  2009-12-30       Impact factor: 8.679

Review 7.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Authors:  T Karantanos; P G Corn; T C Thompson
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

8.  Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Thomas J Schuetz; Brent A Blumenstein; L Michael Glode; David L Bilhartz; Michael Wyand; Kelledy Manson; Dennis L Panicali; Reiner Laus; Jeffrey Schlom; William L Dahut; Philip M Arlen; James L Gulley; Wayne R Godfrey
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

9.  Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.

Authors:  Anna R Kwilas; Andressa Ardiani; Renee N Donahue; Dana T Aftab; James W Hodge
Journal:  J Transl Med       Date:  2014-11-13       Impact factor: 5.531

10.  Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway.

Authors:  Andressa Ardiani; Sofia R Gameiro; Anna R Kwilas; Renee N Donahue; James W Hodge
Journal:  Oncotarget       Date:  2014-10-15
  10 in total
  2 in total

Review 1.  Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.

Authors:  C Alberti
Journal:  G Chir       Date:  2017 Sep-Oct

2.  Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells.

Authors:  Maryam Ghashghaei; Tamim M Niazi; Adriana Aguilar-Mahecha; Kathleen Oros Klein; Celia M T Greenwood; Mark Basik; Thierry M Muanza
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.